ERBB2 and breast cancer: This might explain the negative findings from a recent clinical study reporting that HER2 overexpression does not seem to predispose to locoregional recurrence for breast cancer patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy and radiotherapy [39].